Automate Your Wheel Strategy on GMAB
With Tiblio's Option Bot, you can configure your own wheel strategy including GMAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GMAB
- Rev/Share 283.9994
- Book/Share 83.1065
- PB 18.079
- Debt/Equity 0.027
- CurrentRatio 5.3399
- ROIC 0.9359
- MktCap 92413361030.9556
- FreeCF/Share 99.5834
- PFCF 14.5625
- PE 14.2607
- Debt/Assets 0.0217
- DivYield 0
- ROE 0.2561
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | GMAB | Bernstein | Market Perform | Underperform | -- | -- | April 1, 2025 |
| Upgrade | GMAB | William Blair | Market Perform | Outperform | -- | -- | March 11, 2025 |
| Upgrade | GMAB | Leerink Partners | Market Perform | Outperform | -- | $27 | Feb. 13, 2025 |
| Initiation | GMAB | Redburn Atlantic | -- | Buy | -- | -- | Oct. 8, 2024 |
| Resumed | GMAB | Morgan Stanley | -- | Equal Weight | -- | $31 | Sept. 4, 2024 |
| Downgrade | GMAB | JP Morgan | Overweight | Neutral | -- | -- | Aug. 20, 2024 |
News
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Published: March 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Read More
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Published: March 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 12, 2025, the Company's Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 13,926 restricted stock units to members of the Board of Directors and employees of the Company and the Company's subsidiaries and 4,214 warrants to the employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right …
Read More
Passing of Genmab A/S' Annual General Meeting
Published: March 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement At Genmab A/S' Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approved Discharge was given to the Board of Directors and the Executive Management and the year's profit was carried forward The 2024 Compensation Report was approved Six members of the Board of Directors were re-elected Deloitte was re-elected as the auditor of the Company The proposal from the Board of Directors to adopt amendments to the Remuneration Policy, the proposal on the Board of Directors' remuneration for 2025, the proposal to reduce the Company's share capital with nominally DKK 2,076,853 by …
Read More
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Published: March 10, 2025 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab's rigorous portfolio prioritization, Genmab will not pursue f.
Read More
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; March 4, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Read More
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and employees of the Company as well as the Company's subsidiaries and 517,191 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
Read More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of consensus and expense guidance was surprisingly low, indicating only 7% growth, and enhancing the company's financial outlook. J&J's decision on GEN3014 is pending; I expect J&J to opt out, but remain bullish on Genmab's product portfolio, pipeline, and growth prospects.
Read More
Notice to Convene the Annual General Meeting of Genmab A/S
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 12, 2025, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, and Appendix 2: Proposed amended Remuneration Policy is attached.
Read More
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2024 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2024. Both reports are available via the SEC's website, www.sec.gov and Genmab's website, www.genmab.com.
Read More
Genmab Publishes 2024 Annual Report
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025.
Read More
About Genmab A/S (GMAB)
- IPO Date 2009-06-01
- Website https://www.genmab.com
- Industry Biotechnology
- CEO Jan G.J. van de Winkel
- Employees 2638